Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.53 |
| ▸ | GRN | P28799 | 1/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14300702 | 0.90 | GRN (0.49) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL17436793 | 0.90 | GRN (0.49) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL2243158 | 0.89 | MAPK13 (0.54) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL5822316 | 0.86 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL4504911 | 0.85 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL17436792 | 0.85 | GRN (0.43) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL3432334 | 0.85 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL4133531 | 0.84 | GRN (0.44) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL17436813 | 0.82 | KCNJ6 (0.50) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL4497925 | 0.82 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11GRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024251182-A1 | QUINOXALINE COMPOUND AND USE THEREOF | 广州六顺生物科技有限公司 | 2024-12-12 | — | — | WO | disclosed |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| EP-3418279-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS | Respivert Limited (GB) | 2018-12-26 | — | — | EP | disclosed |
| EP-3105223-B1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LTD (GB) | 2018-09-12 | — | — | EP | disclosed |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170057945-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294216-B2 | Pyrazolyl ureas as kinase inhibitors | MAP3K1, MAP3K2, MAP3K8 | MAPK14 18/4885MAPK13 34/4885MAPK12 43/4885 |
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K7 | MAPK14 16/4885MAPK13 32/4885MAPK12 37/4885 |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | MAPK14 12/4885MAPK13 33/4885MAPK12 37/4885 |
| US-20170057945-A1 | NOVEL COMPOUNDS | MAPK1, MAPK6, MAPKAPK2 | MAPK14 4/4885MAPK13 19/4885MAPK12 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.